Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Sciences profile

Dr Ben Brockway

PositionConsultant in Respiratory Medicine and Senior Lecturer
DepartmentDepartment of Medicine (DSM)
QualificationsMB BS BSc(Hons) MRCP(Lond) FRACP
Research summaryBiomarkers and airway diseases; Cystic Fibrosis
TeachingYear 3 ELM, Year 4 Ambulatory, Year 5 Clinical / ward, Year 6 Supervisor (Tis); Dean's Commendations for Teaching 2009, 2012, 2015; Winner Dean's Senior Staff Award for Quality in Teaching 2011.
MembershipsPrior TSANZ (NZ) Treasurer & Executive member, National Lung Cancer Working Group, SI Lung Cancer Working Group. HRC Clinical Trials Panel Reviewer 2014. Member HRS Executive Board, DSM Executive Board. Member of PHSANZ, TSANZ, ATS, ERS, ECFS.
Clinical

Lead for Cystic Fibrosis care, Pulmonary Hypertension, Interstitial Lung Disease. Also parasomnias and non-respiratory sleep disorders as well as sleep disordered breathing, asthma, COPD, and lung cancer services.

Lead for Cystic Fibrosis care, Pulmonary Hypertension, Interstitial Lung Disease. Also parasomnias and non-respiratory sleep disorders as well as sleep disordered breathing, asthma, COPD ,and lung cancer services.

Research

Dr Ben Brockway studied in the UK and was appointed Consultant and Senior Lecturer in Respiratory Medicine at Dunedin Public Hospital and School of Medicine in 2008. His interests include exhaled breath analysis in disease and health, particularly in the fields of cystic fibrosis, asthma, and COPD. He is PI for numerous studies and his clinical interests include cystic fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and sleep disordered breathing. Clinical trials (commercial or academic) also include bronchiectasis, idiopathic pulmonary fibrosis, insomnia, sleep disordered breathing, pleural disease, asthma, cystic fibrosis, and COPD.

Publications

Amer, M., Cowan, J., Gray, A., Brockway, B., & Dummer, J. (2016). Effect of inhaled β2-agonist on exhaled nitric oxide in chronic obstructive pulmonary disease. PLoS ONE, 11(6), e0157019. doi: 10.1371/journal.pone.0157019

Piccolo, F., Pitman, N., Bhatnagar, R., Popowicz, N., Smith, N. A., Brockway, B., … Lee, Y. C. G. (2014). Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection: An effective and safe alternative to surgery. Annals of the American Thoracic Society, 11(9), 1419-1425. doi: 10.1513/AnnalsATS.201407-329OC

Schrieber, J., Xu-Holland, A., Walker, R., & Brockway, B. (2014). A rare pulmonary complication of myeloma therapy. Breathe, 10(3), 243-248. doi: 10.1183/20734735.014713

Journal - Research Article

Amer, M., Cowan, J., Gray, A., Brockway, B., & Dummer, J. (2016). Effect of inhaled β2-agonist on exhaled nitric oxide in chronic obstructive pulmonary disease. PLoS ONE, 11(6), e0157019. doi: 10.1371/journal.pone.0157019

Piccolo, F., Pitman, N., Bhatnagar, R., Popowicz, N., Smith, N. A., Brockway, B., … Lee, Y. C. G. (2014). Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection: An effective and safe alternative to surgery. Annals of the American Thoracic Society, 11(9), 1419-1425. doi: 10.1513/AnnalsATS.201407-329OC

^ Top of page

Journal - Research Other

Schrieber, J., Xu-Holland, A., Walker, R., & Brockway, B. (2014). A rare pulmonary complication of myeloma therapy. Breathe, 10(3), 243-248. doi: 10.1183/20734735.014713

More publications...